GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Is PRP a Stem Cell Treatment?

No. PRP, or platelet-rich plasma, is a concentrate made from your blood, not a stem cell treatment. Its main ingredients are plasma and platelets: small cell fragments that release signaling proteins, rather than stem cells capable of self-renewal and differentiation. PRP can influence a healing response without transplanting stem cells. Blood basics 37171013

If an offer says “PRP stem cell therapy,” ask whether it means PRP alone or PRP mixed with a separate cell preparation. Request the source and identity of any claimed stem cells; a total cell count alone does not establish that they are stem cells. Whether PRP helps your condition is a separate question. For knee osteoarthritis, a review of 18 placebo-controlled trials involving 1,995 patients found average pain advantages ranging from 0.62 to 1.65 points on a 0–10 scale across follow-up visits. Those results do not establish a stem cell mechanism. PMC11874499

Is PRP a Stem Cell Treatment?

What PRP Contains

A clinician draws blood, uses a centrifuge to concentrate the platelets, and collects the preparation for injection into the treatment site. Platelets participate in clotting and contain growth factors involved in healing. This is a blood-concentration procedure, not a stem cell harvest. Platelet rich plasma prp

PRP is not one fixed formula. Platelet concentration, white-cell content, injected volume, and injection schedule vary. A knee-osteoarthritis review describes reported concentrations of roughly 2.5 to 8 times whole blood and uses a cutoff of 1,000,000 platelets per microliter, with a 20% tolerance, to group studies by platelet concentration. These are preparation characteristics, not measures of stem cell content. PMC11874499

What Makes a Stem Cell Treatment

Stem cells can self-renew and produce specialized descendants. Blood-forming stem cells, for example, give rise to red cells, white cells, and platelets. A platelet is therefore a product of blood-cell development, not itself a blood-forming stem cell. Blood basics

For cultured mesenchymal stromal cells, or MSCs, the International Society for Cellular Therapy proposed minimum laboratory criteria: adherence to plastic in culture; expression of CD73, CD90, and CD105; absence of specified blood and immune markers; and differentiation into bone, fat, and cartilage cell types in vitro. These criteria characterize a laboratory cell population. They do not prove that every cell in a mixed preparation is a stem cell or that an injection will repair cartilage in a patient. 16923606

“Contains living cells” is not enough to distinguish the treatments, because PRP may contain white blood cells. The useful distinction is whether the product is prepared and characterized to deliver stem cells, rather than platelets and their signaling factors. PMC11874499 16923606

Why the Labels Get Mixed Up

Regenerative medicine is an umbrella term, not a statement that a product contains stem cells or has proved that it regenerates tissue. A 2024 narrative review addresses the misconception directly: PRP supplies growth factors and other paracrine signals—messages acting on nearby cells—rather than replacing lost cells with transplanted stem cells. 37171013

A claim that PRP “activates your stem cells” describes a proposed effect on cells already in the body. It does not mean stem cells are in the injection. Laboratory effects on cell activity also do not establish meaningful tissue repair in humans. Ask which cells were studied, whether the evidence involved people with your diagnosis, and what clinical outcome was measured. 37171013

The name of a treatment, the contents of the injection, and proof that it works are three different things.

PRP and Stem Cell Treatments Compared

Feature PRP Stem cell treatment
Main ingredient Concentrated platelets and plasma, sometimes with white blood cells A defined cell preparation intended to deliver stem cells; identity and composition depend on the product
Biological role Releases signaling proteins involved in healing May act through cell replacement, signaling, or immune effects, depending on the product and indication
What needs documenting Platelet concentration, white-cell content, volume, preparation method, and injection schedule Cell source, identity, viable dose, processing, and evidence for the intended use
United States The FDA’s April 2024 consumer guidance warns about unapproved ortho-biologics; it is not a PRP-specific product review. Important patient and consumer information about regenerative medicine therapies Approvals are product- and indication-specific. For example, FDA approved the donor bone-marrow-derived MSC product Ryoncil for steroid-refractory acute graft-versus-host disease in children aged 2 months and older—not for knee arthritis. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
Japan PRP can fall within the regenerative-medicine provision framework; the applicable plan is not an efficacy approval. The ASRM clinical-provision framework and PMD Act product-approval framework serve different purposes. 0003

What PRP Studies Actually Show

Clinical studies address whether a particular PRP protocol improves an outcome. They do not determine whether PRP is a stem cell product. Results from knee injections should not be transferred to scalp treatment or to a PRP-and-cell mixture.

Knee Osteoarthritis

RESTORE was a blinded Australian trial involving 288 adults aged 50 or older with symptomatic medial knee osteoarthritis, Kellgren–Lawrence grades 2–3. Participants received three weekly intra-articular injections of leukocyte-poor PRP or saline. At 12 months, pain decreased by 2.1 points with PRP and 1.8 with saline on a 0–10 scale. The reported between-group difference was −0.4 points (95% CI, −0.9 to 0.2), which was not statistically significant. Medial tibial cartilage volume declined by 1.4% and 1.2%, respectively, also without a significant difference. The trial did not demonstrate cartilage regeneration or a significant pain advantage for this protocol. 34812863

A 2025 meta-analysis, which included RESTORE, pooled 18 placebo-controlled trials with 1,995 patients. Average pain advantages favoring PRP were 0.62 points at one month, 1.43 at three months, 1.65 at six months, and 1.12 at 12 months on a 0–10 scale. The three- and six-month estimates exceeded the review’s chosen 1.37-point threshold for clinical importance. This threshold helps interpret averages; it does not tell you whether an individual patient will notice improvement. PMC11874499

The review rated certainty as moderate for most outcomes; 7 trials had low risk of bias, 9 had some concerns, and 2 had high risk. Its higher-platelet subgroup showed more sustained pain benefits versus placebo than its lower-platelet subgroup. That is an indirect comparison across studies, not proof from a head-to-head trial that increasing platelet concentration will improve your result. PMC11874499

The pooled result and RESTORE are not independent confirmations: RESTORE contributes to the pooled evidence. Different preparations and populations help explain the different findings. For someone considering PRP for knee osteoarthritis, the relevant discussion is the likely symptom benefit and uncertainty for the proposed protocol—not a promise of new cartilage.

Lateral Elbow Tendinopathy

A 2026 meta-analysis of six randomized trials with 338 participants compared PRP with corticosteroid injections for lateral epicondylitis. Corticosteroids performed better within four weeks. At 24 weeks or later, PRP had a mean pain advantage of 1.49 points on a 0–10 scale (95% CI, 0.90 to 2.08 points favoring PRP), just below the authors’ 1.5-point clinical-importance threshold. Certainty was moderate for early and late outcomes and low for intermediate outcomes. This active-treatment comparison does not establish how much either treatment helps relative to placebo. 42859367

Androgenetic Alopecia

A 2026 meta-analysis of nine randomized trials with 451 participants compared PRP with topical minoxidil. The authors reported no clear advantage for hair density or terminal hair count; satisfaction and hair-pull outcomes favored PRP. They also reported high heterogeneity and called for larger standardized trials. Similar results on some outcomes do not establish that the treatments are equivalent. 41219547

Regulation in Japan and the United States

In Japan, the Act on the Safety of Regenerative Medicine, or ASRM, sets requirements for clinical provision, including safety planning and committee review. The PMD Act governs approval and marketing of regenerative medical products. These are distinct regulatory frameworks. 0000150542_00016 0003

A regional MHLW bureau illustrates the PRP procedure using a dental-implant example: in-hospital preparation requires the relevant manufacturing procedure and submission of a provision plan after certified committee review. This example establishes procedural requirements for that situation, not efficacy for every PRP use. Saiseiiryou_yokuarusitumon

A provision plan number is not a PMD Act product approval and does not establish a clinical benefit. Private-clinic availability, self-payment, and “registered in Japan” should not be presented as proof that an injection works.

In the United States, FDA’s consumer page, marked current as of April 8, 2024, warns about unapproved regenerative products, including ortho-biologics, marketed for orthopedic conditions. It does not name PRP specifically and is not a complete current list of cell-product approvals. FDA subsequently approved Ryoncil in December 2024 for the defined pediatric indication described above. That approval does not extend to PRP or to knee arthritis. Important patient and consumer information about regenerative medicine therapies Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Check a named product and its intended use, rather than accepting “FDA registered” or a research-registration number as proof of approval or effectiveness. FDA explicitly warns that firm registration and inclusion on ClinicalTrials.gov do not establish that a regenerative product is legally marketed. Important patient and consumer information about regenerative medicine therapies

Risks and Limits

PRP is not risk-free because it comes from your blood. RESTORE reported minor, transient adverse events, with more knee pain, swelling, and stiffness after PRP than after saline, but no serious related adverse events. That result applies to the studied patients and protocol; it is not a guarantee for every injection. 34812863 Infection, tissue damage, and nerve injury remain procedural concerns. Platelet rich plasma prp

Tell the treating clinician about medicines and bleeding problems before an injection. RESTORE excluded people with a bleeding disorder or ongoing anticoagulation, so its findings should not be assumed to cover those groups. Do not stop prescribed medication without advice from the prescriber. 34812863

Cell products have different, product-specific risks. FDA reports infection, immune reactions, and unwanted tissue growth among risks of unapproved regenerative products; those reports should not be presented as rates of harm from standard PRP. Important patient and consumer information about regenerative medicine therapies No general safety ranking can replace assessment of the exact product, procedure, and patient.

How to Check a Treatment Offer

Reading a Written Quote

If a quote says “PRP + stem cells,” request two separate descriptions: the PRP preparation and the claimed cell product. For the latter, ask for its source, identity, viable dose, processing, and evidence for your diagnosis. A total nucleated-cell count is not a stem cell count. If the paperwork describes only a blood draw and platelet concentration, it does not substantiate a claim that a separate stem cell product is being administered.

Before agreeing to treatment, ask:

  • Is this PRP alone or a combination? What exactly is in each preparation?
  • What are the platelet concentration, white-cell content, injected volume, route, and number of sessions?
  • Which published study matches my diagnosis, disease stage, and proposed product? What outcome improved, by how much, against which comparator, and for how long?
  • If approval is claimed, which regulator approved which product for which indication? In Japan, what is the applicable provision plan?
  • What are the alternatives, risks, total price, follow-up arrangements, and criteria for deciding whether treatment helped?

Claims that need particular scrutiny include:

  • Guaranteed benefit, “no side effects,” or a success rate without a defined outcome, follow-up, and supporting study.
  • Cartilage regrowth without controlled structural evidence, or a promise that you can avoid surgery.
  • “Stem cell therapy” supported only by a total cell count or by the word “regenerative.”
  • A bundled price that never identifies the separate PRP and cell preparations.
  • Intravenous PRP promoted as a whole-body stem cell treatment.

Have questions about an appointment in Japan? Ask the patient support team what information is needed for a clinical consultation.

A treating clinician must assess suitability; an inquiry does not establish eligibility or expected benefit.

Contact the patient support team

Bottom Line

PRP delivers concentrated platelets and their signaling factors, not a stem cell transplant. A knee-osteoarthritis review found an average 1.12-point pain advantage at 12 months, while the included 288-patient RESTORE trial found no significant pain or cartilage-volume benefit for its protocol. PMC11874499 34812863 When an offer combines the two labels, request the exact contents and product-specific evidence before paying.

FAQ

Does PRP Contain Any Stem Cells?

PRP is not prepared or dosed as a stem cell product. Blood can contain circulating blood-forming stem cells, but their presence in blood does not establish a therapeutic stem cell dose in a PRP preparation. The classification depends on what the product is prepared to deliver, not a claim of absolute cell purity. Blood basics 37171013

Can PRP Be Combined With a Cell Product?

A combined offer needs evidence for the actual combination, dose, route, and diagnosis. Adding a separate cell preparation does not change what the PRP component is, and an MSC laboratory marker profile alone does not demonstrate clinical efficacy. 16923606

Does FDA Registration Mean a Treatment Is Approved?

No. FDA warns that registration of a firm or listing in a trial database does not establish legal marketing of a regenerative product. Request the approval information for the named product and intended use. Important patient and consumer information about regenerative medicine therapies

Should I Assume Insurance Will Pay?

No. Obtain written confirmation from your insurer and an itemized quote from the provider before booking. In Japan, do not infer insurance coverage from a provision plan number.

Evidence and Scope

The clinical discussion uses published trial reports and reviews, not testimonials. The knee trial and meta-analysis were checked in full text; the elbow and hair-loss summaries rely on their published abstracts. This guide does not report firsthand treatment experience, patient interviews, or an examination of an individual’s medical records. The written-quote example is a practical checking exercise, not an observed clinical case.

Sources were checked on October 24, 2026, with selected clinical and regulatory sources rechecked on October 29, 2026. Internal links lead to site information or appointment support, not independent proof of efficacy. This is general information, not a diagnosis or personalized treatment recommendation; an appropriately qualified clinician must assess individual care.